ClinicalTrials.gg
Sign In

Hemoglobinopathies clinical trials

The registry lists 100 studies for Hemoglobinopathies across more than 10 countries. 29 are recruiting or about to start. 23 of them are mainly about Hemoglobinopathies (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 7 narrower conditions too, such as Anemia, Sickle Cell: 1,579 studies, 333 open.

Get an email when these change. Save the Hemoglobinopathies studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
42
Recruiting
24
Terminated
12
Active, not recruiting
12
Not yet recruiting
3
Status unknown
3

Phase

Phase 2
37
Phase 1
20
Phase 3
10
Early Phase 1
4
Phase 4
3

Where

United States
58
Italy
16
United Kingdom
13
Canada
12
Germany
10
Spain
5

Who runs them

Vertex Pharmaceuticals Incorporated (6) · University of California, San Francisco (5) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Baylor College of Medicine (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Società Italiana Talassemie ed Emoglobinopatie (3) · Editas Medicine, Inc. (3) · Bellicum Pharmaceuticals (3)

What is being tested here

Drugs under test in Hemoglobinopathies studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Exagamglogene autotemcel266
Fludarabine104
Busulfan102
Sirolimus102
Mycophenolic Acid102
Tacrolimus102
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs101
Senicapoc101
Cell Types101
Plerixafor101

Drug classes tested here Calcineurin inhibitors 2 open · Antimetabolites 1 open · Alkylating agents 1 open

Coming up

5phase 3 studies under way
10studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 10, phase 3 first

Who these studies take

Of the 24 Hemoglobinopathies studies recruiting now, 7 (29%) set no upper age limit and 14 (58%) stop at 75 or younger. 20 (83%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (13%) take healthy volunteers.

Recruiting studies that take each age, of 24
AgeWomenMen
1015 (63%)15 (63%)
1823 (96%)23 (96%)
3018 (75%)18 (75%)
4014 (58%)14 (58%)
5013 (54%)13 (54%)
6510 (42%)10 (42%)
7510 (42%)10 (42%)
8510 (42%)10 (42%)

Across all 100 studies, recruiting or not: 71% stop at 75 or younger and 68% at 65; 77% take children; 3% are for women only and 0% for men only; 12% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Hemoglobinopathies studies take

Of 21 observational studies under Hemoglobinopathies, half reached primary completion within 53 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational53 mo28–68 · 21 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 100. Browse all 100 → or search them.